Desjardins Global Asset Management Inc. Regeneron Pharmaceuticals, Inc. Transaction History
Desjardins Global Asset Management Inc.
- $922 Million
- Q4 2023
A detailed history of Desjardins Global Asset Management Inc. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Desjardins Global Asset Management Inc. holds 873 shares of REGN stock, worth $510,975. This represents 0.08% of its overall portfolio holdings.
Number of Shares
873
Previous 1,355
35.57%
Holding current value
$510,975
Previous $1.12 Million
31.3%
% of portfolio
0.08%
Previous 0.12%
Shares
9 transactions
Others Institutions Holding REGN
# of Institutions
1,441Shares Held
88.9MCall Options Held
1.98MPut Options Held
1.75M-
Vanguard Group Inc Valley Forge, PA9.42MShares$5.52 Billion0.08% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$4.94 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY5.66MShares$3.31 Billion0.28% of portfolio
-
State Street Corp Boston, MA4.83MShares$2.83 Billion0.1% of portfolio
-
Dodge & Cox San Francisco, CA3.83MShares$2.24 Billion1.21% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $62.7B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...